A transcatheter functional valve replacement for tricuspid valve insufficiencybroad
Trillium · Horizon Europe grant · 2022-06-01–2026-05-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2021-ACCELERATOROPEN-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2021-ACCELERATOROPEN-01. CORDIS record →
Objective
Tricuspid regurgitation (TR) is a cardiac disorder in which the tricuspid valve leaks during systole causing blood backflow, resulting in decreased cardiac output. TR is the most common valvular heart disease affecting 65%-85% of the global population in its mild form. However, mild TR can progress to severe TR, leading to heart failure or death if left untreated. Today, the only option for treatment is valve repair or replacement through open-heart surgery, which is associated with high mortality rates, risks, and costs. Over 3M patients suffer from TR in Europe, and for the majority, their condition is too severe for surgery; therefore, there is no effective treatment. Innoventric has developed the Trillium - a transcatheter tricuspid valve replacement solution: the whole procedure is minimally invasive and can be completed in 30mins. Within the EIC project, Innoventric will finalize the clinical validation of its device, ensuring safe and timely intervention for TR patients.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| INNOVENTRIC LTD | IL | coordinator | €2,500,000 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.